Autoimmunity EQA Programmes

Our Autoimmunity EQA programmes provide laboratories with the opportunity to assess, compare and improve performance in the detection and measurement of autoantibodies.

These schemes support UK proficiency testing and quality assurance in autoimmunity, helping laboratories maintain confidence in results, meet accreditation standards, and demonstrate competence to regulators and peers.

Alongside our EQA services, UK NEQAS IIA provides a range of autoimmunity educational resources through the Digital Academy, including webinars, commentaries, and technical presentations that support continued professional development in autoimmunity testing.

All schemes below are administered by UK NEQAS for Immunology, Immunochemistry & Allergy (UK NEQAS IIA) and are open to national and international participants.

Programmes in this category

• Acetylcholine Receptor Antibody (SER/008)
  External quality assurance for AChR antibody testing in myasthenia gravis.

• Anaemia Related Antibodies (SER/034)
  Detection of gastric parietal cell antibodies to support investigation of autoimmune anaemia.

• ANCA and GBM (SER/007)
  Testing for anti-neutrophil cytoplasmic and glomerular basement membrane antibodies.

• Antibodies to Nuclear and Related Antigens (SER/003 & SER/005)
  Assessment of ANA, DNA and ENA antibody detection across autoimmune connective-tissue disorders.

• Anti-Phospholipid Antibodies (SER/006)
  Evaluation of anti-cardiolipin and related antibodies involved in anti-phospholipid syndrome.

• Bullous Dermatosis Antibodies (SER/009)
  Assessment of antibodies associated with blistering skin diseases.

• Coeliac Disease Antibodies (SER/010)
  Measurement of anti-tTG and EMA antibodies for coeliac disease screening and diagnosis.

• Interferon Gamma Release Assays (SER/039)
  Quality assurance for IGRA tests used in tuberculosis screening.

• Liver Disease Antibodies (SER/004)
  Identification of antibodies associated with autoimmune liver disease, including AMA, LKM and SMA.

• Rheumatoid Antibodies (SER/001 & SER/036)
  Assessment of rheumatoid factor and anti-citrullinated protein antibodies to aid accurate diagnosis of rheumatoid arthritis.

• Thyroid Antibodies (SER/002 & SER/048)
  Evaluation of thyroid microsome (TPO) and TSH receptor antibodies for autoimmune thyroid disease.
  
  
• COVID-19/SARS CoV-2 Antibodies (SER/059)
  Detection of antibodies to SARS-CoV-2 / COVID-19 confirming previous infection
  
  
• Diabetic Markers (SER/047)
  Aiding the clinical diagnosis of type I diabetes
  
  
• Ganglioside Antibody (SER/050)
  Diagnosis of neuropathy syndromes
  
  
• Myositis Associated Antibodies (SER/054)
  Assessment of myositis‑associated autoantibodies linked to overlap connective‑tissue diseases and inflammatory myopathies.
  
  
• Myelin Associated Glycoprotein IgM Antibodies (SER/057)
  IgM anti – MAG found in sensory motor neuropathies and IgM paraprotein associated neuropathies
  
  
• Paraneoplastic Antibodies (SER/038)
  Paraneoplastic autoantibodies are seen with a variety of neurological manifestations and can be associated with an underlying malignancy
  
  
• Autoimmune Encephalitis Associated Antibodies - Pilot EQA (SER/062)
  Identification of antibodies associated with autoimmune encephalitis with no known common infectious cause
  
  
• Phospholipase Receptor 2 Antibodies (SER/055)
  Primary (idiopathic) membranous nephropathy

How participation supports quality

Participating in UK NEQAS IIA Autoimmunity EQA schemes allows laboratories to:

• Benchmark performance against peer institutions.
• Demonstrate competence for UKAS and other regulatory bodies.
• Identify areas for improvement through educational feedback reports.
• Maintain high standards of analytical and interpretative performance.

Register Today

Don’t hesitate to contact us for further information, and register here today.